Medical device innovator ABK Biomedical has raised $35 million USD ($49.1 million CAD) in Series D funding to bring its Eye90™ microspheres, a next-generation treatment for liver cancer, to market.
Your go-to source for the latest Startup developments.
Would you like us to send you the latest news from the startup world?